內地中成藥全國集採擬平均降價逾49%
據《中國證券報》報道,全國中成藥採購聯盟集中帶量採購產生擬中選結果於周三(21日)出爐。
據悉,在湖北召開全國中成藥採購聯盟集中帶量採購現場報價訊息公開大會上,共有86家企業、95個報價代表品參與現場競爭。63家企業、68個報價代表品中選,中選率達71.6%,中選品種平均降幅49.36%。
根據此前文件顯示,此次集採由湖北省牽頭30省(區、市)組成聯盟,對復方斑蝥、復方血栓通、冠心寧、華蟾素等16個中成藥進行集中帶量採購,涉眾生藥業(002317.SZ)、亞寶藥業(600351.SH)及益佰製藥(600594.SH)等A股上市公司。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.